Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$0.76 - $1.78 $32,452 - $76,006
42,700 Added 32.91%
172,439 $156,000
Q2 2022

Aug 15, 2022

SELL
$1.28 - $2.31 $588 - $1,062
-460 Reduced 0.35%
129,739 $180,000
Q1 2022

May 16, 2022

BUY
$1.82 - $3.5 $37,450 - $72,019
20,577 Added 18.77%
130,199 $294,000
Q3 2021

Nov 15, 2021

BUY
$2.59 - $3.36 $22,274 - $28,896
8,600 Added 8.51%
109,622 $294,000
Q2 2021

Aug 16, 2021

SELL
$3.11 - $4.87 $1.41 Million - $2.21 Million
-454,350 Reduced 81.81%
101,022 $338,000
Q1 2021

May 17, 2021

BUY
$3.66 - $7.67 $347,392 - $728,005
94,916 Added 20.61%
555,372 $2.39 Million
Q4 2020

Feb 16, 2021

BUY
$3.03 - $5.51 $94,923 - $172,617
31,328 Added 7.3%
460,456 $1.91 Million
Q3 2020

Nov 10, 2020

SELL
$2.9 - $4.29 $13,891 - $20,549
-4,790 Reduced 1.1%
429,128 $1.44 Million
Q2 2020

Aug 14, 2020

BUY
$1.99 - $3.64 $863,496 - $1.58 Million
433,918 New
433,918 $1.36 Million

Others Institutions Holding GNPX

About Genprex, Inc.


  • Ticker GNPX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,020,300
  • Market Cap $76.8M
  • Description
  • Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...
More about GNPX
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.